Transcriptomic Profiling of Cumulus Cells From CAPA-IVM
Recruiting · NCT07197255 · Observational (researchers observe without assigning treatment) · Lead sponsor: Mỹ Đức Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.
Who can take part
Inclusion criteria
- Women 18-38 years
- BMI =\< 32kg/m2
- Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and/or biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound.
- Indicated for CAPA-IVM treatment.
- Serum AMH ≥ 4 ng/mL (28.57 pmol/L).
- Antral follicle count (AFC) ≥ 24 follicles in both ovaries at the time of CAPA-IVM indication.
- Signed informed consent to participate in the study.
Exclusion criteria
- Retrieved sperm from surgical procedures
- Previous IVF cycle with total immature oocytes
Where it is running
1 location listed.
- My Duc Hospital - Ho Chi Minh City, Vietnam